看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.9x - 5.5x | 5.2x |
| Historical Pb Multiple | 3.2x - 6.4x | 5.9x |
| Fair Value | ₩22,516 - ₩24,886 | ₩23,701 |
| Upside | -16.0% - -7.1% | -11.6% |
| Benchmarks | - | Full Ticker |
| Oscotec Inc. | - | KOSDAQ:A039200 |
| Mezzion Pharma Co.,Ltd. | - | KOSDAQ:A140410 |
| Hanall Biopharma Co., Ltd. | - | KOSE:A009420 |
| JETEMA, Co., Ltd. | - | KOSDAQ:A216080 |
| Komipharm International Co., Ltd. | - | KOSDAQ:A041960 |
| Caregen Co., Ltd. | - | KOSDAQ:A214370 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| A039200 | A140410 | A009420 | A216080 | A041960 | A214370 | |||
| KOSDAQ:A039200 | KOSDAQ:A140410 | KOSE:A009420 | KOSDAQ:A216080 | KOSDAQ:A041960 | KOSDAQ:A214370 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | 2.9% | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | 8.5% | ||
| Latest Twelve Months | 103.6% | -53.0% | -151.4% | -101.3% | 429.6% | -19.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -361.4% | -80.4% | 7.9% | 4.0% | -17.6% | 45.1% | ||
| Prior Fiscal Year | -490.4% | -40.1% | 2.6% | 23.8% | -9.3% | 50.4% | ||
| Latest Fiscal Year | 2.6% | -226.2% | -1.3% | -0.3% | 22.3% | 39.1% | ||
| Latest Twelve Months | 2.6% | -226.2% | -1.3% | -0.3% | 22.3% | 39.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -34.4% | -41.2% | 5.1% | 3.6% | -6.4% | 14.7% | ||
| Prior Fiscal Year | -21.9% | -29.0% | 2.0% | 21.7% | -6.8% | 18.0% | ||
| Latest Twelve Months | 0.8% | -36.2% | -1.0% | -0.3% | 22.1% | 14.4% | ||
| Next Fiscal Year | 9.7% | 151.8% | 3.8% | 10.5% | 9.9% | 20.6% | ||
| Two Fiscal Years Forward | 42.1% | 70.1% | 6.1% | 30.6% | 16.4% | 24.8% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 35.7x | 124.2x | 10.0x | 4.2x | 5.5x | 15.9x | ||
| Price / LTM EPS | 1383.3x | -54.9x | -770.7x | -1515.6x | 24.7x | 40.5x | ||
| Price / Book | 9.5x | 23.2x | 8.3x | 3.9x | 5.2x | 5.9x | ||
| Price / Fwd Book | 8.6x | 3.2x | 8.0x | 3.6x | 5.0x | 5.6x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 3.9x | 8.3x | 23.2x | |||||
| Historical P/B Ratio | 3.2x | 5.9x | 6.4x | |||||
| Selected P/B Multiple | 4.9x | 5.2x | 5.5x | |||||
| (x) Book Value | 222,978 | 222,978 | 222,978 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A039200 | A140410 | A009420 | A216080 | A041960 | A214370 | |
| Value of Common Equity | 1,212,467 | 1,069,691 | 1,390,978 | 285,322 | 323,403 | 1,309,737 | |
| (/) Shares Outstanding | 38.2 | 30.0 | 50.8 | 35.8 | 69.7 | 48.9 | |
| Implied Stock Price | 31,700.00 | 35,700.00 | 27,400.00 | 7,960.00 | 4,640.00 | 26,800.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 31,700.00 | 35,700.00 | 27,400.00 | 7,960.00 | 4,640.00 | 26,800.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |